Skip to content
Search

Latest Stories

MHRA issues drug recall for MidaBuc-Midazolam10mg Oromucosal Solution

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a medicines recall for MidaBuc – Midazolam (as HCL) 10mg/ml Oromucosal Solution of Eastone Ltd.

The manufacturer Eaststone Ltd. has informed the MHRA of an issue related to underfilled or empty bottles for MidaBuc – Midazolam (as HCL) 10mg/mL Oromucosal Solution.


Product details

Batch NumberExpiry DatePack SizeFirst Distributed
ES8455315 April 20215ml26 April 2019

Clonidine hydrochloride 50micrograms/5ml oral solution of SyriMed with PL 39307/0082 is also being recalled.

SyriMed is recalling the above batch as a precautionary measure due to an issue related to the container closure (child-lock cap).

Product details

Batch NumberExpiry DatePack SizeFirst Distributed
201014September 2022100ml19th November 2020

 

“The Marketing Authorisation Holder has received a number of complaints related to defective container closures and the investigation has identified an issue with the bottle capping during the manufacturing process for the batch,” the MHRA said.

Pharmacies have been advised to stop supplying the medicines batches immediately and quarantine all remaining stock and return it to their supplier using the concerned supplier’s approved process.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less